Episode
Shaun Noorian (Empower Pharmacy CEO) - GLP-1s, Patents, and the Future of Compounding
- Podcast
- Hims House
- Published
- Aug 19, 2025
- Duration seconds
- 3913
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/shaun-noorian-empower-pharmacy-ceo-glp-1s-patents-and-the-future-of-compounding/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hims-house-7026583/shaun-noorian-empower-pharmacy-ceo-glp-1s-patents-and-the-future-of-compounding.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In Episode 42 of Hims House, Jonathan Stern and Patrick Lester (Bayside) sit down with Shaun Noorian, founder & CEO of Empower Pharmacy, the world’s largest compounding pharmacy. We dig into why rumors about 503Bs “ramping up GLP-1s” may be misleading, how Empower is challenging Eli Lilly on tirzepatide patents, and the broader fight over compounding. We also how Trump’s new administration - RFK Jr. at HHS, and Marty Makary at FDA - could reshape the industry. We close with the MFN pricing backdrop under the new administration. All along the way, Noorian makes the case that compounding is not a loophole but a critical, highly regulated part of healthcare, and looks ahead to its future in hormone therapy, peptides, longevity medicine, and sleep health. 00:00 – Intro 00:52 – Empower’s mission: personalized medicine at scale 03:07 – GLP-1 rumors: are 503Bs ramping? What’s actually legal 09:21 – 503A vs. 503B compliance 19:14 – The Eli Lilly v. Empower lawsuit 27:04 – MFN pricing, EO chatter & compounding 33:11 – Hims’ impact on the industry: awareness, lobbying & demand 37:15 – HRT, peptides, longevity 39:59 – Sermorelin explained 41:32 – Bad actors vs. legitimate compounders 43:08 – Odds: percent chance of FDA action against compounders Get full access to Hims House at himshouse.substack.com/subscribe